Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesMerck and Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection
Merck & Co., 04/22/09
Merck and Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories of the University of Massachusetts Medical School announced that they have signed an exclusive worldwide license agreement for CDA-1 and CDB-1, an investigational fully human monoclonal antibody combination developed to target and neutralize Clostridium difficile toxins A and B, for the treatment of C. difficile infection. CDA-1 and CDB-1 were co-developed by Medarex and MBL.
Today in Licensure/Accreditation...keeping you current
Receive free subspecialty "5-minute updates" via email
New ncqa disease management standards focus on measurement, quality improvement and transparency
National Committee for Quality Assurance (NCQA), 12/15/09
EDI Accrediting Firm Updates Criteria
HealthDataManagement, 12/09/09
Consumer Demand for H1N1 Information Highlights Importance of Accreditation for Health Call Centers
URAC News Releases, 12/07/09
Article Search
Sponsor